Moore Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Moore Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-27,578	Closed	-$149K	–	485
2022 Q4	$149K	Sell	27,578 -395,324	-93%	-$2.66M	﹤0.01%	382
2022 Q3	$4.24M	Buy	422,902 +64,420	+18%	+$370K	0.1%	226
2022 Q2	$1.69M	Hold	358,482	–	–	0.04%	359
2022 Q1	$1.4M	Hold	358,482	–	–	0.04%	410
2021 Q4	$2.42M	Sell	358,482 -11,101	-3%	-$122K	0.05%	381
2021 Q3	$5.49M	Buy	+369,583	New	+$6.15M	0.08%	233

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Moore Capital Management's ABOS Position: Q1 2023 in Review

Moore Capital Management sold out of Acumen Pharmaceuticals (ABOS) in Q1 2023, closing a stake of 27,578 shares — an estimated $149K sold.

Moore Capital Management first reported a position in ABOS in Q3 2021 and held it in 6 quarters. The position peaked at $5.49M in Q3 2021. 61 funds tracked by Wall St. Rank hold ABOS as of Q1 2023.

Moore Capital Management reported no remaining Acumen Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Moore Capital Management sold 27,578 Acumen Pharmaceuticals shares in Q1 2023, an estimated $149K.
Moore Capital Management first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 6 quarters.
Moore Capital Management's Acumen Pharmaceuticals position peaked at $5.49M in Q3 2021.
61 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2023.

Based on Moore Capital Management's 13F filing for Q1 2023, filed 15 May 2023.